1
|
Plasma Cell Immunophenotyping Improve Prognostic Stratification of Multiple Myeloma Patients. INTERNATIONAL JOURNAL OF CANCER MANAGEMENT 2018. [DOI: 10.5812/ijcm.5350] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Wang HY, Zu Y. Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry. Arch Pathol Lab Med 2017; 141:1236-1246. [PMID: 28608720 DOI: 10.5858/arpa.2016-0521-ra] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT - Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity. OBJECTIVES - To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells. DATA SOURCES - Published and PubMed-indexed English literature was reviewed. CONCLUSIONS - Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1+ large B-cell lymphoma.
Collapse
|
3
|
Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci 2016; 17:ijms17101760. [PMID: 27775669 PMCID: PMC5085784 DOI: 10.3390/ijms17101760] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Revised: 09/26/2016] [Accepted: 10/05/2016] [Indexed: 02/06/2023] Open
Abstract
Plasma cell myeloma is a clinically heterogeneous malignancy accounting for approximately one to 2% of newly diagnosed cases of cancer worldwide. Treatment options, in addition to long-established cytotoxic drugs, include autologous stem cell transplant, immune modulators, proteasome inhibitors and monoclonal antibodies, plus further targeted therapies currently in clinical trials. Whilst treatment decisions are mostly based on a patient’s age, fitness, including the presence of co-morbidities, and tumour burden, significant scope exists for better risk stratification, sub-classification of disease, and predictors of response to specific therapies. Clinical staging, recurring acquired cytogenetic aberrations, and serum biomarkers such as β-2 microglobulin, and free light chains are in widespread use but often fail to predict the disease progression or inform treatment decision making. Recent scientific advances have provided considerable insight into the biology of myeloma. For example, gene expression profiling is already making a contribution to enhanced understanding of the biology of the disease whilst Next Generation Sequencing has revealed great genomic complexity and heterogeneity. Pathways involved in the oncogenesis, proliferation of the tumour and its resistance to apoptosis are being unravelled. Furthermore, knowledge of the tumour cell surface and its interactions with bystander cells and the bone marrow stroma enhance this understanding and provide novel targets for cell and antibody-based therapies. This review will discuss the development in understanding of the biology of the tumour cell and its environment in the bone marrow, the implementation of new therapeutic options contributing to significantly improved outcomes, and the progression towards more personalised medicine in this disorder.
Collapse
|
4
|
Di Lullo G, Marcatti M, Heltai S, Brunetto E, Tresoldi C, Bondanza A, Bonini C, Ponzoni M, Tonon G, Ciceri F, Bordignon C, Protti MP. Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. Oncoimmunology 2015; 4:e1005460. [PMID: 26155400 PMCID: PMC4485827 DOI: 10.1080/2162402x.2015.1005460] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Revised: 12/30/2014] [Accepted: 12/30/2014] [Indexed: 12/19/2022] Open
Abstract
There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III and relapsed/refractory MM patients compared with healthy donors and patients with asymptomatic or stage I/II disease. Th22 cells cloned from the BM of MM patients were CCR6+CXCR4+CCR4+CCR10- and produced IL-22 and IL-13 but not IL-17. Furthermore, polyfunctional Th22-Th2 and Th22-Th1 clones were identified based on the co-expression of additional chemokine receptors and cytokines (CRTh2 or CXCR3 and IL-5 or interferon gamma [IFNγ], respectively). A fraction of MM cell lines and primary tumors aberrantly expressed the IL-22RA1 and IL-22 induced STAT-3 phosphorylation, cell growth, and resistance to drug-induced cell death in MM cells. IL-13 treatment of normal BM mesenchymal stromal cells (MSCs) induced STAT-6 phosphorylation, adhesion molecule upregulation, and increased IL-6 production and significantly favored MM cell growth compared with untreated BM MSCs. Collectively, our data show that increased frequency of IL-22+IL-17-IL-13+ T cells correlates with poor prognosis in MM through IL-22 and IL-13 protumor activity and suggest that interference with IL-22 and IL-13 signaling pathways could be exploited for therapeutic intervention.
Collapse
Key Words
- Ab, antibody; BM, bone marrow; BMMCs, bone marrow mononuclear cells; DCs, dendritic cells; Dx, dexamethasone; ICS, intracellular cytokine staining; IFN, interferon; IL, interleukin; ISS, International Staging System; LCL, Epstein–Barr virus-transformed B lymphoblastoid cell line; Ln, lenalidomide; MGUS, monoclonal gammopathy of undetermined clinical significance; MM, multiple myeloma; MSC, mesenchymal stromal cell; PB, peripheral blood; PBMCs, peripheral blood mononuclear cells; pDCs, plasmacytoid dendritic cells; SMM, smoldering multiple myeloma; Th, T helper; TNF, tumor necrosis factor; Treg, regulatory T cells; WB, Western blot
- CD4+ T helper lymphocytes
- IL-22RA1
- Th22 cells
- bone marrow mesenchymal stromal cells
- bone marrow microenvironment
- interleukin-13
- interleukin-22
- multiple myeloma
Collapse
Affiliation(s)
- Giulia Di Lullo
- Tumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Magda Marcatti
- Hematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Silvia Heltai
- Tumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Emanuela Brunetto
- Tumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Cristina Tresoldi
- Hematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Attilio Bondanza
- Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Leukenia Immunotherapy Group; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Chiara Bonini
- Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Experimental Hematology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Maurilio Ponzoni
- Pathology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Molecular Oncology; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Giovanni Tonon
- Division of Molecular Oncology; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Functional Genomics of Cancer Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Fabio Ciceri
- Hematology and Bone Marrow Transplantation Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| | - Claudio Bordignon
- MolMed SpA ; Milan, Italy ; Vita-Salute San Raffaele University ; Milan, Italy
| | - Maria Pia Protti
- Tumor Immunology Unit; IRCCS San Raffaele Scientific Institute ; Milan, Italy ; Division of Immunology, Transplantation and Infectious Diseases; IRCCS San Raffaele Scientific Institute ; Milan, Italy
| |
Collapse
|
5
|
Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. BIOMED RESEARCH INTERNATIONAL 2014; 2014:893243. [PMID: 24991573 PMCID: PMC4065753 DOI: 10.1155/2014/893243] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Revised: 04/28/2014] [Accepted: 05/08/2014] [Indexed: 01/04/2023]
Abstract
We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38–78). Analyzed clinical characteristics and laboratory parameters were as follows: serum β2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (P = 0.049) and LDH (P = 0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33− patients (P = 0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS; P = 0.001 and P = 0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS; P = 0.037) and OS (P = 0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.
Collapse
|
6
|
Bai LY, Weng JR, Tsai CH, Sargeant A, Lin CW, Chiu CF. OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways. Leuk Res 2009; 34:816-20. [PMID: 20006997 DOI: 10.1016/j.leukres.2009.11.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2009] [Revised: 11/16/2009] [Accepted: 11/18/2009] [Indexed: 11/16/2022]
Abstract
Although c-Kit is expressed on the surface of myeloma cells in one-third of myeloma patients, the efficacy of imatinib mesylate for patients with myeloma is still controversial. To investigate the combinatorial effect of OSU-03012 and imatinib mesylate, we treated a c-Kit-expressing myeloma cell line, TIB-196, with DMSO, OSU-03012 alone, imatinib mesylate alone and OSU-03012 plus imatinib mesylate. OSU-03012 sensitized TIB-196 cells to imatinib mesylate cytotoxicity. p-STAT3 (Tyr705), as well as down-stream cyclin D1 and Mcl-1, was down regulated. Additionally, there was markedly increased p-AMPK (Thr172) and down-regulation of p-p70S6K (Thr386) in the combination group. Combined treatments targeting c-Kit, AMPK and STAT3 may be a potential strategy for treating patients with myeloma.
Collapse
Affiliation(s)
- Li-Yuan Bai
- Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan
| | | | | | | | | | | |
Collapse
|
7
|
Herbert KE, Prince HM, Ritchie DS, Seymour JF. The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin Biol Ther 2009; 10:113-25. [DOI: 10.1517/14712590903473123] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma 2009; 50:137-40. [PMID: 19152174 DOI: 10.1080/10428190802563363] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Tanya M Wildes
- Division of Geriatrics and Nutritional Science, St Louis, MO 63110, USA.
| | | | | | | | | |
Collapse
|
9
|
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008; 112:1346-56. [PMID: 18524994 DOI: 10.1182/blood-2007-10-116590] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Inhibition of multiple myeloma (MM) plasma cells in their permissive bone marrow microenvironment represents an attractive strategy for blocking the tumor/vessel growth associated with the disease progression. However, target specificity is an essential aim of this approach. Here, we identified platelet-derived growth factor (PDGF)-receptor beta (PDGFRbeta) and pp60c-Src as shared constitutively activated tyrosine-kinases (TKs) in plasma cells and endothelial cells (ECs) isolated from MM patients (MMECs). Our cellular and molecular dissection showed that the PDGF-BB/PDGFRbeta kinase axis promoted MM tumor growth and vessel sprouting by activating ERK1/2, AKT, and the transcription of MMEC-released proangiogenic factors, such as vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). Interestingly, pp60c-Src TK-activity was selectively induced by VEGF in MM tumor and ECs, and the use of small-interfering (si)RNAs validated pp60c-Src as a key signaling effector of VEGF loop required for MMEC survival, migration, and angiogenesis. We also assessed the antitumor/vessel activity of dasatinib, a novel orally bioactive PDGFRbeta/Src TK-inhibitor that significantly delayed MM tumor growth and angiogenesis in vivo, showing a synergistic cytotoxicity with conventional and novel antimyeloma drugs (ie, melphalan, prednisone, bor-tezomib, and thalidomide). Overall data highlight the biologic and therapeutic relevance of the combined targeting of PDGFRbeta/c-Src TKs in MM, providing a framework for future clinical trials.
Collapse
|
10
|
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF. Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. J Clin Oncol 2008; 26:2737-44. [DOI: 10.1200/jco.2007.15.4120] [Citation(s) in RCA: 164] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). Patients and Methods We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry, in a series of 685 newly diagnosed MM patients that were uniformly treated according to the GEM 2000 protocol. Results Our results show that expression of both CD19 and CD28 as well as the absence of CD117 were associated with a significantly shorter progression free-survival (PFS) and overall survival (OS). Interestingly, the CD28 expression correlated with t(14;16) and del(17p), while CD117-negative patients were associated with t(4;14) and del(13q). Simultaneous assessment of CD28 and CD117 antigens allowed stratification of patients with MM into three risk categories: poor risk (CD28 positive CD117 negative), intermediate (either both markers negative or both positive), and good risk (CD28 negative CD117 positive), with PFS rates of 30, 37, and 45 months, respectively (P = .01), and OS rates of 45, 68, and not reached, respectively (P = .0001). Conclusion To the best of our knowledge, this is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens (particularly CD28 and CD117) on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
Collapse
Affiliation(s)
- Gema Mateo
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - M. Angeles Montalbán
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria-Belén Vidriales
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Juan J. Lahuerta
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria V. Mateos
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Norma Gutiérrez
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Laura Rosiñol
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Laura Montejano
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Joan Bladé
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Rafael Martínez
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Javier de la Rubia
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Joaquín Diaz-Mediavilla
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Anna Sureda
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - José M. Ribera
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - José M. Ojanguren
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Felipe de Arriba
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Luis Palomera
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Maria J. Terol
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Alberto Orfao
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| | - Jesús F. San Miguel
- From the Hospital Universitario de Salamanca; Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca; Hospital 12 de Octubre; Clínico San Carlos, Madrid; Clínic Universitari Barcelona; Hospital Sant Pau Barcelona; Hospital La Fé; Clínico Universitario, Valencia; Hospital Germans Trias i Pujol Badalona; Hospital de Galdakao; Hospital Morales Messeguer, Murcia; and the Hospital Lozano Blesa, Zaragoza, Spain
| |
Collapse
|
11
|
Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2007; 32:379-82. [PMID: 17767956 DOI: 10.1016/j.leukres.2007.07.016] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2007] [Revised: 07/17/2007] [Accepted: 07/23/2007] [Indexed: 10/22/2022]
Abstract
CD117 (c-kit) was evaluated on normal plasma cells (PC) (n=10), PC of individuals with monoclonal gammopathy of undetermined significance (MGUS, n=12), malignant PC from patients with multiple myeloma (MM) either at diagnosis (n=83) or relapse (n=38) and on 23 human myeloma cell lines (HMCL). Whereas CD117 is never expressed in normal PC, it is expressed in 50% of MGUS (p=0.015). Furthermore, 33% of MM at diagnosis do express CD117, as opposed to 8% of those in relapse (p=0.003). Finally, CD117 was never found in HMCL. CD117 expression was associated with a better prognosis: overall survival was 93% at 4 years in CD117+ MM versus 64% in CD117- MM (p=0.05). Conversely, lack of CD117, but also high beta-2 microglobulin, t(4;14) and CD221 (IGF-1R) expression were associated with a poorer prognosis. Multivariate analysis revealed that CD117- patients were those with CD221 and t(4;14) and had the poorest prognosis. In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM.
Collapse
|
12
|
Kisseberth WC, Nadella MVP, Breen M, Thomas R, Duke SE, Murahari S, Kosarek CE, Vernau W, Avery AC, Burkhard MJ, Rosol TJ. A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res 2007; 31:1709-20. [PMID: 17532464 DOI: 10.1016/j.leukres.2007.04.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2006] [Revised: 03/14/2007] [Accepted: 04/02/2007] [Indexed: 11/29/2022]
Abstract
A novel canine lymphoma cell line, OSW, was established from the malignant pleural effusion of a dog with peripheral T-cell lymphoma. The immunoprofile as determined by flow cytometry was as follows: positive for CD45, CD49d, CD18, CD11a; weakly positive for CD11b, CD11c, CD11d; and negative for CD45RA, CD1a, CD1c, CD3, TCRalphabeta, TCRgammadelta, CD4, CD5, CD8a, CD8b, CD90(Thy1), CD21, MHCII, CD14(TUK4), CD34, and MPO. Immunocytochemistry of cytospin preparations was negative for cytoplasmic CD3, CD79a, and MPO, but was positive for CD20. The cell line had an oligoclonal T-cell receptor gamma (TCRgamma) gene rearrangement. Array comparative genomic hybridization (aCGH) and single locus probe (SLP) analysis showed that there were copy number increases of loci on dog chromosome 13 (CFA 13), and copy number decreases were evident for regions of CFA 11, 22, 26, 30 and 32, which include several of the more common chromosomal aberrations reported previously in canine lymphoma. The OSW cell line grows rapidly in vitro and is tumorigenic as a xenograft in SCID/NOD mice. OSW represents one of only a few reported canine lymphoma cell lines and is the most thoroughly characterized. This cell line and xenograft represent significant in vitro and in vivo models, respectively, for comparative and translational lymphoma research.
Collapse
Affiliation(s)
- William C Kisseberth
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|